Ardelyx (NASDAQ:ARDX) Insider Joseph James Reilly Sells 4,991 Shares

Ardelyx, Inc. (NASDAQ:ARDX) insider Joseph James Reilly sold 4,991 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $5.85, for a total transaction of $29,197.35. Following the completion of the transaction, the insider directly owned 151,790 shares of the company’s stock, valued at approximately $887,971.50. This represents a 3.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ardelyx Stock Up 0.3%

ARDX stock opened at $5.75 on Tuesday. The company has a 50 day moving average price of $6.76 and a two-hundred day moving average price of $6.13. The company has a debt-to-equity ratio of 1.21, a quick ratio of 4.11 and a current ratio of 4.31. The stock has a market capitalization of $1.40 billion, a P/E ratio of -23.00 and a beta of 0.57. Ardelyx, Inc. has a one year low of $3.21 and a one year high of $8.40.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). The business had revenue of $125.22 million for the quarter, compared to analyst estimates of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.Ardelyx’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.02 EPS. As a group, sell-side analysts expect that Ardelyx, Inc. will post -0.18 EPS for the current year.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the stock. SEC Filing: Director Purchase
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set a $19 price target (large upside vs. current levels), which can attract buyers and boost sentiment. Wedbush Note via Benzinga
• Positive Sentiment: Other firms reiterated bullish views (BTIG buy rating; HC Wainwright optimistic on FY2026 earnings), reinforcing analyst support that can sustain buying interest. BTIG Reiteration HC Wainwright Note
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and year-over-year revenue growth of ~7.8% — a constructive fundamental datapoint, though offset by an EPS miss. (Earnings release was on Feb 19.)
• Negative Sentiment: Earnings EPS missed expectations (reported a loss vs. small expected profit), which triggered a sell-off (shares were reported down ~10.4% after the earnings release). EPS misses typically pressure sentiment and can lead to continued volatility. Earnings Reaction
• Negative Sentiment: Multiple insiders — including the CEO, CFO and several executives — sold shares on Feb 20 (notably the CEO sold ~45,982 shares). Clustered insider selling can be read as profit-taking or reduced insider conviction and may weigh on sentiment. (These sales occurred near $5.85.) SEC Filing: CEO Sale

Institutional Trading of Ardelyx

Several large investors have recently bought and sold shares of ARDX. First Horizon Corp grew its holdings in Ardelyx by 120.4% during the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 4,319 shares in the last quarter. DCF Advisers LLC purchased a new stake in shares of Ardelyx during the second quarter worth about $39,000. Brighton Jones LLC acquired a new position in shares of Ardelyx in the second quarter worth about $40,000. SBI Securities Co. Ltd. boosted its holdings in Ardelyx by 147.0% in the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 6,102 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. acquired a new stake in Ardelyx during the 4th quarter valued at approximately $60,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ARDX shares. Wedbush restated an “outperform” rating and set a $19.00 price objective on shares of Ardelyx in a report on Monday. Raymond James Financial restated a “strong-buy” rating and set a $19.00 price target on shares of Ardelyx in a research note on Thursday, January 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Ardelyx in a research note on Tuesday, January 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Ardelyx in a report on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and set a $17.00 price objective on shares of Ardelyx in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $15.09.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.